Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-AV-1451 PET Imaging and Tau Pathology Autopsy Study
NCT02350634Phase 1Completed
- Sponsor
- Avid Radiopharmaceuticals
- Start
- Nov 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of flortaucipir in Alzheimer's disease (AD), sponsored by Avid Radiopharmaceuticals. Primary endpoints: Relationship of Flortaucipir Scan and Pathology - Whole Cortical Composite Region, Relationship of Flortaucipir Scan and Pathology - Frontal Composite Region and 5 more. Started Nov 2016; status: completed.
02
Drugs
flortaucipir
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02350634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02350634.